The cancer treatment paradigm is changing with innovative breakthrough therapies becoming available but at increasing cost and with more barriers to access.  We are seeing the arrival of immunotherapies, virus and carT therapy with high effectivity in treating cancer patients. Given these breakthrough therapies,flexibility of regulatory processes and heath technology assessments is required.  Affordability and sustainability continue to be major concerns where the dialogue needs to move away from cost to value-based outcomes.

CONECTed Issues [brochure]